Compounds & Therapies
Bimagrumab (BYM338)
Bimagrumab (BYM338) is a fully human monoclonal antibody that binds and blocks the activin receptor type II (ActRII), preventing signaling from myostatin, activin A, and other ActRII ligands that negatively regulate skeletal muscle mass. By blocking…
Bupropion-Naltrexone (Contrave)
Bupropion-naltrexone sustained-release (brand name Contrave) is an FDA-approved combination weight-loss drug, approved in September 2014. It pairs bupropion — a norepinephrine and dopamine reuptake inhibitor used as an antidepressant and…
Setmelanotide (Imcivree)
Setmelanotide (brand name Imcivree, Rhythm Pharmaceuticals) is a melanocortin-4 receptor (MC4R) agonist administered as a daily subcutaneous injection. It is FDA-approved for chronic weight management in patients aged 6 years and older with obesity…